Simon Bekker-Jensen

Lead optimization and pre-clinical testing of a NASH therapeutic with a novel mode of action

From left to right: Goda Snieckute, Simon Bekker-Jensen and Anna Constance Vind.

Applicant

Simon Bekker-Jensen

Project description

Non-alcoholic fatty liver (NAFLD) disease affects 1 out of 4 people worldwide. In 30% of the cases, it develops to the more severe and irreversible form, non-alcoholic steatosis (NASH), which can lead to cirrhosis, liver cancer and ultimately liver failure for which there is no treatment except transplantation.

We have identified a new mechanism of action that drives both NAFLD and NASH in a mouse model of obesity. During the SPARK program, we aim to achieve proof-of-concept with a model compound that targets the above mechanism. If successful, this compound may constitute the basis for pharmaceutical and clinical development of novel anti-NASH therapeutics.

Institution

University of Copenhagen